Primary peritoneal carcinomaNews & Research
11 curated articles for Primary peritoneal carcinoma — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Annals of surgical oncology Apr 27, 2026
ASO Author Reflections: Surgical Radicality Versus Aggressive Biology: Small Bowel and Ileocecal Involvement Predict Poorer Survival Despite Complete Cytoreduction in FIGO IIIC-IV Tubo-Ovarian and Primary Peritoneal Carcinoma.
ASO Author Reflections: Surgical Radicality Versus Aggressive Biology: Small Bowel and Ileocecal Involvement Predict Poorer Survival Despite Complete Cytoreduction in FIGO IIIC-IV Tubo-Ovarian and Primary Peritoneal Carcinoma.
Why it matters: Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
- Cureus Apr 27, 2026
Primary Peritoneal High-Grade Serous Carcinoma Presenting With Diffuse Carcinomatosis and No Ovarian Mass: A Case of Exceptional Response.
Primary peritoneal serous carcinoma (PPSC) is a rare Müllerian malignancy that closely resembles ovarian carcinoma but is distinguished by minimal or absent ovarian involvement despite extensive peritoneal disease. Diagnosis becomes particularly challenging when no adnexal mass is identifi...
Why it matters: Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
- Annals of surgical oncology Apr 26, 2026
ASO Visual Abstract: Ileocecal and Small-Bowel Involvement are Independently Associated with Inferior Survival Despite Complete Cytoreduction in FIGO IIIC-IV Tubo-Ovarian and Primary Peritoneal Carcinoma.
ASO Visual Abstract: Ileocecal and Small-Bowel Involvement are Independently Associated with Inferior Survival Despite Complete Cytoreduction in FIGO IIIC-IV Tubo-Ovarian and Primary Peritoneal Carcinoma.
Why it matters: Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
- Lancet (London, England) Apr 19, 2026
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study.
Epithelial ovarian cancer frequently recurs and becomes resistant to platinum chemotherapy. We investigated whether adding pembrolizumab to weekly paclitaxel, with or without bevacizumab, improves progression-free survival and overall survival compared with weekly paclitaxel, with or without bevaciz...
Why it matters: Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
- Annals of surgical oncology Apr 12, 2026
Ileocecal and Small Bowel Involvement Are Independently Associated with Inferior Survival Despite Complete Cytoreduction in FIGO IIIC-IV Tubo-Ovarian and Primary Peritoneal Carcinoma.
Complete macroscopic tumor resection is the strongest prognostic factor in advanced epithelial tubo-ovarian and primary peritoneal cancer, yet benefit from maximum-effort cytoreductive surgery may vary with tumor distribution and site-specific resections. We aimed to identify predictors of long-term...
Why it matters: Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
- Cancers Mar 28, 2026
Heterogeneity in Stage IV Ovarian Cancer: Survival Trends in Patients Presenting with Sister Mary Joseph's Nodule.
Background/Objectives : Sister Mary Joseph's nodule (SMJN) is classified as FIGO stage IVb in ovarian cancer. While traditionally considered an indicator of poor prognosis, emerging evidence suggests variable outcomes. This study aimed to describe overall survival (OS) and recurrence-free survival (...
Why it matters: Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
- Journal of clinical medicine Mar 28, 2026
Primary Peritoneal Low-Grade Serous Carcinoma in a 16-Year-Old Female: A Case Report.
Background : Primary peritoneal carcinoma (PPC) is an uncommon malignancy typically diagnosed in postmenopausal women, accounting for less than 1% of all gynecologic cancers. Its occurrence in adolescents is extremely rare. We present a case of a 16-year-old female with low-grade serous carcinoma (L...
Why it matters: Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
- Hereditary cancer in clinical practice Mar 22, 2026
A retrospective analysis of risk-reducing salpingo-oophorectomy performed in women diagnosed with hereditary breast and ovarian cancer at our institution.
Hereditary breast and ovarian cancer (HBOC) confers a markedly increased lifetime risk of breast and ovarian cancers. As no effective surveillance method for early detection of ovarian cancer has been established, risk-reducing salpingo-oophorectomy (RRSO) is recommended for patients with HBOC to pr...
Why it matters: Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
- Communications medicine Mar 14, 2026
Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial.
Epigenetic modulators may sensitize platinum-resistant ovarian cancer (PROC) to immune checkpoint inhibition by reprogramming the tumor microenvironment. We report clinical and translational findings from a phase II non-randomized study of pembrolizumab and oral azacitidine in 34 women with PROC (NC...
Why it matters: Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
- Frontiers in oncology Mar 9, 2026
Treatment with Mirvetuximab-Soravtansin-first clinical experience in advanced ovarian cancer in a comprehensive cancer center.
Mirvetuximab-Soravtansin (MIRV) is an antibody-drug conjugate (ADC) for the therapy of advanced platinum-resistant folate receptor α (FRα)-expressing ovarian cancer. The goal of the study was to treat patients with MIRV off-label in our Comprehensive Cancer Center regarding the outcome a...
Why it matters: Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
- International journal of gynecological cancer : official journal of the International Gynecological Cancer Society Feb 5, 2026
Oncologic outcomes of incidental serous tubal intraepithelial carcinoma and associated high-grade serous carcinoma in high-risk patients undergoing risk-reducing surgery.
We sought to describe the oncologic outcomes of isolated serous tubal intraepithelial carcinomas compared to an intraepithelial carcinoma found concurrently with microscopic high-grade serous carcinoma among patients with hereditary predisposition to ovarian cancer who underwent risk-reducing surger...
Why it matters: Recent peer-reviewed research on Primary peritoneal carcinoma that may be relevant for patients and caregivers.
More on Primary peritoneal carcinoma
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.